Similarly compared with discontinuation of RASi, the REPLACE COVID (the randomized elimination or prolongation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in coronavirus disease 2019) trial found that continuation of RASi had no effect on a composite global rank score as a marker for COVID‐19 severity.8 The gene discussed is MMP19; the disease is COVID-19.